Abstract
The triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor that affects cellular phenotypes by modulating phagocytosis and metabolism, promoting cell survival, and counteracting inflammation. Its role in renal injury, in particular, unilateral ureteral obstruction (UUO) or ischemia-reperfusion injury (IRI)-induced renal injury remains unclear. In our study, WT and Trem2−/− mice were employed to evaluate the role of TREM2 in renal macrophage infiltration and tissue injury after UUO. Bone marrow-derived macrophages (BMDM) from both mouse genotypes were cultured and polarized for in vitro experiments. Next, the effects of TREM2 on renal injury and macrophage polarization in IRI mice were also explored. We found that TREM2 expression was upregulated in the obstructed kidneys. TREM2 deficiency exacerbated renal inflammation and fibrosis 3 and 7 days after UUO, in association with reduced macrophage infiltration. Trem2−/− BMDM exhibited increased apoptosis and poorer survival compared with WT BMDM. Meanwhile, TREM2 deficiency augmented M1 and M2 polarization after UUO. Consistent with the in vivo observations, TREM2 deficiency led to increased polarization of BMDM towards the M1 proinflammatory phenotype. Mechanistically, TREM2 deficiency promoted M1 and M2 polarization via the JAK-STAT pathway in the presence of TGF-β1, thereby affecting cell survival by regulating mTOR signaling. Furthermore, cyclocreatine supplementation alleviated cell death caused by TREM2 deficiency. Additionally, we found that TREM2 deficiency promoted renal injury, fibrosis, and macrophage polarization in IRI mice. The current data suggest that TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway. These findings have implications for the role of TREM2 in the regulation of renal injury that justify further evaluation.
Subject terms: Mechanisms of disease, Cell death and immune response
Introduction
Inflammation and fibrosis are common pathological manifestations of progressive, chronic kidney disease (CKD) that eventually result in end-stage renal disease [1]. It has been documented that prolonged and excessive inflammation plays a significant role in the development of fibrosis [2, 3]. The pathogenesis of the unilateral ureteral obstruction (UUO) animal model mirrors that of human obstructive nephropathy. Specifically, complete blockage of the renal system leads to damage of tubular epithelial cells, resulting in a notable increase in markers of renal fibrosis, such as inflammation mediated by macrophages and activation of myofibroblasts [4]. Furthermore, renal IRI involves a sequence where the kidney experiences an ischemic phase followed by reperfusion under specific conditions. Despite reperfusion, renal function does not recover but rather exacerbates the damage. The pathophysiology of IRI is intricate, encompassing various factors that contribute to kidney injury and fibrosis [5]. Additionally, an increasing number of studies have acknowledged the key and complex role of macrophages in renal inflammation and fibrosis [6, 7]. Macrophage plasticity plays an important role in the process from renal inflammation to renal fibrosis, which is an important step in the development of end-stage renal disease. On one end of the spectrum, M1 macrophages, which are proinflammatory, play a role in clearing infections but can also exacerbate renal damage. Conversely, M2 macrophages, which are anti-inflammatory, possess a reparative phenotype but also exacerbate renal fibrosis [8]. Despite this understanding, the precise mechanisms involved in these processes are not fully elucidated, and effective treatments are currently lacking.
Triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor expressed on myeloid cells, including immature dendritic cells [9], osteoblasts [10], microglia [11, 12], and other macrophages [13, 14]. It consists of an extracellular domain that includes a single V-type immunoglobulin domain, a short ectodomain, a single transmembrane helix, and a short cytosolic tail that lacks any signal transduction or trafficking motifs [15]. TREM2 binds to the junctional proteins DNAX activation protein 10 (DAP10) or DAP12, resulting in the activation of phosphoinositide 3-kinase (PI3K) or spleen tyrosine kinase (Syk), which in turn mediate downstream signaling [16]. Furthermore, TREM2 has been reported to regulate inflammatory signaling and microglial metabolism and to promote microglial phagocytosis, activation, survival, and proliferation [17, 18]. Most studies on TREM2 have focused on microglia in the brain. However, the role of TREM2 in liver and lung injury has also been studied in recent years. For example, Perugorria et al. reported that Trem2−/− mice exhibited more severe liver injury and inflammation during acute and chronic CCl4 and acetaminophen intoxication [19]. Moreover, Vincent et al. observed that Trem2−/− mice experienced worse LPS-induced acute lung injury [20], while Nakao et al. documented more severe liver ischemia-reperfusion injury (IRI) in Trem2−/− mice [21]. Nevertheless, the influence of TREM2 on macrophages and underlying mechanisms during the progression of renal injury/fibrosis remains unclear.
In this study using a mouse model of unilateral ureteral obstruction (UUO), we observed a significant increase in expression of TREM2 with duration of disease in injured kidneys compared to sham controls. Consistent with our hypothesis, renal inflammation and fibrosis were exacerbated in UUO mice lacking TREM2. This was accompanied by a decrease in kidney-infiltrating macrophages, while the incidence of M1 and M2 cells increased. In vitro experiments revealed that TREM2 deficiency resulted in the downregulation of the mammalian target of rapamycin (mTOR) signaling and induced macrophage apoptosis. Conversely, TREM2 deficiency triggered activation of the JAK-STAT pathway to promote macrophage polarization towards M1 and M2. Furthermore, the data from another renal fibrosis mouse model, IRI, had consistent results. We demonstrated that TREM2 significantly improved IRI- and UUO-induced kidney injury by alleviating inflammation and fibrosis, and potently abrogated the transition to CKD.
Methods and materials
Animal experiments
WT mice used in these experiments were male C57BL/6J mice aged 8 to 12 weeks and were purchased from SLAC Jingda Laboratory Animal Co. Ltd (Hunan, China). Trem2 knockout (Trem2−/−) mice were generated using conventional homologous recombination methods by Cyagen Biosciences, Inc. (Suzhou, China). The offspring were genotyped using PCR according to the manufacturer’s protocol (Cyagen, Suzhou, China). The UUO and IRI model were established as previously described [22, 23]. The UUO mouse models were euthanized on day 3 or day 7 after the UUO or sham operation. The IRI mice models were euthanized on day 7. Kidney tissues were harvested for various molecular and histological studies.
RNA extraction and quantitative real-time PCR (qRT-PCR)
Kidney tissue and cell pellets were harvested. Total RNA was extracted using TRIzol reagent according to the manufacturer’s instructions (Vazyme, Nanjing, China), and cDNA was synthesized using the reverse transcription system kits (Vazyme). Real-time PCR was performed using the SYBR Green qPCR Master Mix kit (Bimake, Houston, TX, USA). Primer sequences for the analyzed genes are listed in Table S1. Quantitative PCR data were analyzed using the 2−∆∆ct method.
Immunofluorescence (IF) staining
For IF studies, kidney tissues were embedded at the optimal cutting temperature (OCT) immediately after the mice were euthanized. OCT-embedded kidneys were cryosectioned into 5-μm sections and mounted on adhesion slides. The sections were fixed with cold methanol for 20 min, blocked with 5% v/v goat serum for 1 h at room temperature (RT), and incubated with primary antibodies against TREM2 (Proteintech, Wuhan, China), F4/80 (Servicebio, Wuhan, China), kidney injury molecule-1 (KIM-1; Novus, Port Orchard, WA, USA), inducible nitric oxide synthase (iNOS; Servicebio), CD206 (Servicebio), and Arg1 (Servicebio). The secondary antibodies used were Alexa Fluor 488 and Alexa Fluor 594 (Servicebio). The sections were then stained with 40, 6-diamidino-2phenylindole. All images were captured using a confocal microscope (ECLIPSE Ti; Nikon, Tokyo, Japan).
Kidney histology
The kidneys embedded in paraffin were sectioned at 5 μm thickness and stained with hematoxylin and eosin using standard methods. Indices of tubular damage (tubular dilation, cell necrosis, infarction, and cast formation) were assessed by calculating the percentage of the renal cortex that displayed these features [24]. Histological assessment was performed in a blinded fashion in five randomly selected fields (original magnification × 100).
TdT-mediated dUTP nick end labeling (TUNEL) staining
TUNEL staining to detect cell death was performed using a commercially available in situ cell death detection kit (Servicebio) according to the manufacturer’s instructions.
Immunohistochemistry and Masson staining
The kidney tissues were fixed in 4% v/v paraformaldehyde for 48 h, dehydrated using a graded ethanol series, embedded in paraffin, and sectioned (5 μm). For immunohistochemical staining, antigen retrieval was performed using a citrate solution after deparaffinization and rehydration. The sections were blocked with 5% v/v goat serum and then incubated with the following primary antibodies at 4 °C overnight: collagen-I (col-I; Abcam, Cambridge, England) and α-smooth muscle actin (α-SMA; Abcam). The sections were then incubated with biotinylated secondary antibodies (Abcam) for 2 h at RT and streptavidin-peroxidase complex for 1 h at RT then visualized with a 3,3′-diaminobenzidine system according to the manufacturer’s protocol. The sections were counterstained with hematoxylin and dehydrated. The dehydrated sections were mounted using neutral resin. Masson’s trichrome staining was performed according to the manufacturer’s instructions (Servicebio). Quantification of collagen-I-, α-SMA-, and Masson-positive areas was performed by taking random cortical images (original magnification power × 40, six fields per kidney) of renal cortex from each mouse and counting the percentages of the positively-stained areas in each microscopic field.
Cell culture and treatment
Murine bone marrow-derived macrophages (BMDM) were generated using a procedure similar to that described previously [25, 26]. Briefly, the BM was isolated from the tibias and femurs and cultured in DMEM (CGM102.05, Cellmax, Beijing, China.) containing 10% v/v fetal bovine serum (FBS; 10100147, Gibco, Grand Island, NY, USA), 20 ng/mL macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapolis, MN, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were allowed to differentiate into macrophages for 7 days. On day 7, BMDMs were cultured for 24 h in complete media alone (M0) or media supplemented with 50 ng/mL LPS (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/mL IL-4 (PeproTech, Rocky Hill, NJ, USA) or 5 ng/mL TGF-β1 (R&D Systems). After incubation, cells were washed with sterile PBS and used for experimental assays.
Tissue harvest for single-cell suspension and flow cytometric analysis
Single-cell suspensions were isolated from murine kidneys by digestion with collagenase and DNaseI. Erythrocytes were lysed using an ammonium chloride potassium lysis buffer. The cells were collected by centrifugation (500 × g for 5 min at RT) and washed with phosphate-buffered saline containing 2% v/v FBS. The cells were stained with Zombie Aqua (BioLegend, San Diego, CA) and treated with FcγR-blocking rat anti-mouse CD16/32 Ab (Cat# 101320; BioLegend). For surface staining, cells were incubated for 30 min at 4 °C with different combinations of fluorochrome-conjugated Abs, including CD45.2 (Cat# 103116), CD11b (Cat# 101216), F4/80 (Cat# 123107), CD86 (Cat# 105028) and major histocompatibility complex class II (MHC II, CD274; 10F.9G2, BioLegend). For intracellular staining, cells were fixed and permeabilized using a Fixation and Permeabilization reagent (BioLegend), followed by incubation with CD206 (Cat# 141708, BioLegend). All flow cytometry data were acquired using an LSR-Fortessa flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo version 10 software (Tree Star, San Carlos, CA).
Cell counting kit-8 (CCK-8) assay
Cells were seeded in 96-well culture plates (1 × 105/well) and incubated at 37 °C in a 5% CO2 incubator. The old solution was discarded on days 1–7 and 95 μL of RPMI-1640 medium and 5 μL of CCK-8 was added to each well of the 96-well plate to be tested, then incubated at 37 °C for 2 h. A microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) was used to measure the optical density (OD) of each well at 450 nm and to detect changes in the cell proliferation ability of each group. In the 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine) experiments, 10 nM cyclocreatine was added on days 3, 4, and 5 to the BM cell culture.
Western blotting
BMDMs were lysed in RIPA buffer containing a protease and phosphatase inhibitor cocktail (Coolabor, Beijing, China). Protein concentration was determined using the BCA assay (Vazyme). Equal amounts of protein were loaded onto a 4–12% sodium dodecyl sulfate-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The membrane was blocked with 5% v/v milk and incubated overnight at 4 °C with the primary antibodies (listed in Table S2). After the membranes were washed with TBST buffer 3 times, they were probed with secondary antibodies (Antgene, Wuhan, China) for 1 h at RT and then visualized using an enhanced chemiluminescence kit (Advance Targeting System, San Diego, CA, USA).
RNA-seq
Transcriptome sequencing of BMDM was performed by GENE DENOVO Co. Ltd (Guangzhou, China). Genes with significantly different expression levels (upregulated by at least twofold or downregulated by at least 0.5-fold) in Trem2−/− BMDM compared to WT BMDM were selected for further analysis. Genes that were commonly upregulated or downregulated in Trem2−/− BMDM were identified and analyzed using the KEGG pathway database (http://www.genome.jp/kegg/). Hierarchical clustering of differential gene expression patterns was performed and heat maps were used to present the clustering results. Subsequently, GSEA analysis of the KEGG pathway was performed.
Statistical analyses
All data were presented as mean ± standard deviation (SD) values and tested for normal distribution. Statistical analyses were conducted using GraphPad Prism 8.0. The t-test was utilized to compare two groups, while the one-way analysis of variance (ANOVA) with post hoc Tukey multiple comparison tests was used to compare more than two groups. P < 0.05 was considered statistically significant.
Results
TREM2 was upregulated in the obstructed kidney
First, we investigated the expression of TREM2 in UUO kidneys. While qPCR analysis did not detect Trem2 mRNA in sham kidneys, it was significantly upregulated in obstructed kidneys (Fig. 1a). Indeed, Trem2 mRNA levels in obstructed kidneys on postoperative day (POD) 7 were significantly upregulated than that observed in the sham group. Additionally, IF staining of TREM2 in the kidneys demonstrated a similar pattern (Fig. 1b). Subsequently, to ascertain the cellular localization of TREM2 in the kidneys, double IF staining was conducted. The findings indicated a strong co-localization of TREM2 and the macrophage marker F4/80 (Fig. 1c), suggesting that macrophages in the kidney are the predominant cell type that expresses TREM2, consistent with previous reports [15, 27, 28]. These findings suggest that TREM2 is a crucial regulator in UUO progression and deserves our further investigation.
TREM2 deficiency aggravated UUO-induced renal injury, renal cell apoptosis, and inflammation
Next, the effect of TREM2 on renal injury induced by UUO was explored. Trem2−/− mice exhibited significant exacerbation of UUO-induced tubular damage, characterized by cortical tubular dilation accompanied by tubular epithelial cell necrosis, brush border loss, intratubular cast formation, and immune cell infiltration (Fig. 2a). However, no significant difference was observed in the levels of serum creatinine (Cr) and blood urea nitrogen (BUN) between WT and Trem2−/− mice on POD3, 7, and 14, compared with the sham group (Fig. S1). In addition, TREM2 deficiency had no significant effect on systemic immune infiltration and inflammatory response (Fig. S2). This may be due to an existing compensatory functional role of the contralateral healthy kidney [29, 30]. Therefore, we examined the expression of KIM-1, an important molecular indicator of renal injury [31]. Both qRT-PCR and IF results revealed that the KIM-1 expression level was significantly higher in the UUO kidneys of Trem2−/− mice compared with the UUO kidneys of WT mice (Fig. 2b, c).
Moreover, renal apoptosis plays a crucial role in the pathogenesis of UUO [32]. In the current study, TUNEL analysis indicated that the renal cell apoptosis induced by UUO was significantly increased in Trem2−/− mice (Fig. 2d), indicating that TREM2 deficiency led to increased apoptosis in the UUO kidneys. Furthermore, inflammatory cytokines, including TNF-α, IL-1β, and IL-6, are produced and secreted by inflammatory cells, such as macrophages, during UUO progression and can reflect the level of inflammation [33, 34]. As expected, on POD3 and 7, TNF-α, IL-1β, and IL-6 mRNA levels were significantly higher in the UUO kidneys of Trem2−/− compared with WT mice (Fig. 2e). Overall, the above data indicate that TREM2 deficiency significantly exacerbates tubular injury, renal inflammation, and renal cell apoptosis in UUO kidneys.
TREM2 deficiency aggravated UUO-induced renal fibrosis
Blocked urinary flow upon UUO leads to tubular injury, which in turn, leads to renal fibrosis [35]. To further investigate the influence of TREM2 on kidney fibrosis in mice with UUO, we performed Masson staining on UUO kidneys of both WT and Trem2−/− mice. A significant increase in the extent of fibrosis was then observed in Trem2−/− mice on POD7 (Fig. 3a). In addition, immunohistochemical analysis was performed to assess the expression levels of col-I and α-SMA, classic profibrotic markers, in the UUO kidneys of WT and Trem2−/− mice. Significant increases in the levels of col-I and α-SMA were observed (Fig. 3b, c). Taken together, these results indicate that TREM2 deficiency significantly exacerbates renal fibrosis following UUO.
TREM2 deficiency inhibited macrophage survival in UUO kidneys and BMDMs
Extensive research has consistently demonstrated that renal inflammatory cell infiltration, particularly the infiltration of macrophages, plays a prominent role in UUO pathogenesis [36, 37]. To explore the mechanism underlying the regulation of UUO macrophages by TREM2, we assessed infiltrating macrophages (CD11b+ F4/80+) within the UUO kidneys. The results indicate a significant decrease in the proportion of infiltrating macrophages in UUO kidneys of Trem2−/− compared to WT mice on POD3, with a further reduction on POD7 (Fig. 4a, gating strategy provided in Figure S3). Similarly, IF staining revealed that the number of F4/80+ cells (macrophages) infiltrating UUO kidneys of Trem2−/− mice was significantly reduced on POD3 and POD7 (Fig. 4b). These data indicate that TREM2 deficiency markedly attenuated macrophage infiltration in UUO kidneys.
To further ascertain the influence of TREM2 on macrophage development/survival in vitro, we assessed apoptosis/survival of BMDM on day 5 of culture. The results show that TREM2 deficiency significantly increased the incidence of early apoptotic cells (Annexin V+ PI−) in BMDM (Fig. 4c). Moreover, the CCK-8 assay demonstrated that TREM2 deficiency significantly inhibited cell survival during the development of BM cells into macrophages, and that the difference was most significant on day 4 (Fig. 4d). Furthermore, immunoblotting results indicated that anti-apoptotic protein Bcl2 was significantly downregulated in Trem2−/− BMDM, while the cleaved-caspase 3/pro-caspase 3 level was upregulated (Fig. 4e), confirming that apoptosis was enhanced in Trem2−/− BMDM compared to WT BMDM. Collectively, these data suggest that TREM2 deficiency promotes macrophage apoptosis and inhibits its survival.
TREM2 deficiency impaired mTOR signaling in BMDM
In order to explore the specific mechanisms by which TREM2 acts on macrophages, we performed transcriptomic assays on WT and Trem2−/− BMDM, given that we couldn’t obtain sufficient quantities of viable cellular material from macrophage of FACS sorting from the WT and Trem2−/− mice with UUO. Then, transcriptomic data were analyzed for differentially expressed genes (DEGs) with a false discovery rate (FDR) < 0.05 and |Fold Change| > 2 (Fig. 5a). As shown in Fig. 5b, we evaluated functional associations according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. We noted that the apoptotic pathway was in the top 15 enrichment pathways, confirming that TREM2 deficiency influenced the regulation of apoptosis. In the cluster heatmap of differential gene expression shown in Fig. 5c, a significant downregulation in the expression of anti-apoptosis-related proteins, such as Bcl2, Bcl2l1, and Fos was observed. Additionally, the expression of mTOR signaling-related proteins, such as Slc7a5 and Igf1 was significantly downregulated. In summary, the transcriptomic data obtained from BMDM indicate that TREM2 deficiency may inhibit macrophage survival through downregulation of the mTOR pathway.
The mTOR signaling is a classical pathway that regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation and is closely associated with cell survival and apoptosis [38, 39]. We then assessed the expression of key proteins involved in mTOR signaling in WT and Trem2−/− BMDM. Immunoblotting results revealed that the phosphorylation levels of mTOR and Akt were significantly reduced in Trem2−/− BMDM, whereas the expression level of p70S6 kinase (S6K), a downstream molecule of mTORC1, was significantly upregulated (Fig. 5d). Given the inhibitory effect of TREM2 deficiency on mTOR activation in BMDM, we attempted to overcome this deficiency by employing alternative approaches that bypassed TREM2. The creatine analog cyclocreatine produces a long-lasting phosphate upon phosphorylation, which is effective in maintaining cellular ATP levels during increased energy demand [40]. We added cyclocreatine to BMDM cultures and performed a CCK-8 assay, which revealed a significant improvement in survival of Trem2−/− BMDM, and in some cases, the addition of cyclocreatine even led to a reversal of survival outcome (Fig. 5e), thus validating our conclusion that TREM2 regulates macrophage survival through the Akt/mTOR pathway.
TREM2 deficiency promoted macrophage polarization in UUO kidneys and BMDM
In addition to cell survival, macrophage polarization has been reported to be a key factor in UUO progression [41–43]. Through IF detection of iNOS and the mannose receptor CD206 in the UUO kidney, we noted an increased proportion of both iNOS+ cells and CD206+ cells in kidneys of Trem2−/− mice on POD3 and POD7 (Fig. 6a, b). Additionally, both F4/80-positive iNOS+ and Arg1+ cells were elevated in the kidney tissues of POD7 mice (Fig. S4a, b). Subsequently, we assessed the percentages of M1 and M2 macrophages in the UUO kidneys using flow cytometry. The results revealed a significant increase in the proportion of CD86+ macrophages (M1) in the UUO kidneys of Trem2−/− mice on POD3 and POD7 (Fig. 6c). Moreover, M1 macrophages are proinflammatory cells characterized by high expression of MHC II, CD80, CD86, CD38, and TLR4 [44]. MHC II+ macrophages were also significantly elevated in the UUO kidneys of Trem2−/− mice on POD3 (Fig. S4c, d). Interestingly, TREM2 deficiency resulted in a significant increase in M1 macrophages in the kidneys of sham mice (Figs. 6d and S4e). This suggests that TREM2 exerts a regulatory effect on macrophage polarization in kidneys that are not obstructed. Furthermore, the proportion of CD206+ cells was significantly higher in the UUO kidneys of Trem2−/− mice (Fig. 6e). In addition, absolute counts of CD206+ cells indicated that TREM2 deficiency significantly increased M2 macrophages in UUO kidneys (Fig. 6f). These data suggest that TREM2 deficiency significantly promoted macrophage polarization toward M2 in UUO kidneys.
Consistent with our in vivo findings, the proportion of Trem2−/− BMDM polarized into M1 cells following LPS stimulation was higher compared to WT BMDM. Moreover, the proportion of Trem2−/− BMDM polarized into M2 was notably higher than that of WT BMDM following IL-4 stimulation (Fig. 7a). To reflect the UUO environment as far as possible in vitro, we drew on insights from previous studies [45, 46] and used TGF-β1 to stimulate the BMDM. The TGF-β superfamily is the most widely studied macrophage-derived growth factor and is a key inducer of the epithelial-mesenchymal transition (EMT) process in renal fibrosis [47]. Our data reveal that following TGF-β1 stimulation, expression of the M1 marker CD86 by Trem2−/− BMDM was significantly higher, while expression of the M2 marker CD206 tended to increase, although not significantly (Fig. 7b). Furthermore, we conducted transcriptomic sequencing analysis on the M0, M1, and M2 subtypes of BMDM, respectively. Our findings reveal a general upregulation of key markers associated with M1 and M2 polarization in Trem2−/− BMDM (Fig. 7c, d), which further suggests that TREM2 deficiency promotes polarization of macrophages towards M1 and M2 phenotypes.
TREM2 deficiency regulated JAK-STAT signaling pathway
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway has been studied extensively and found to play a crucial role in kidney inflammation by regulating the expression of diverse inflammatory molecules [48, 49], which in turn regulate M1/M2 polarization of macrophages [50]. To verify whether TREM2 exerted a regulatory effect on macrophage polarization through the JAK-STAT pathway, we assessed the expression of key proteins of JAK-STAT signaling in WT and Trem2−/− BMDM in control and TGF-β1-stimulated groups, respectively. The results show that TREM2 deficiency substantially reduced phosphorylation levels of JAK2 in both control and TGF-β1-stimulated groups. Additionally, the phosphorylation levels of STAT1 and STAT3 were significantly increased in Trem2−/− BMDM following TGF-β1 stimulation (Fig. 7e, f). In summary, our findings suggest that TREM2 deficiency promotes macrophage polarization by regulating JAK2-STAT1/3 signaling, which in turn, exacerbates UUO tubular injury, renal inflammation, and interstitial fibrosis.
Moreover, a recent study has reported that crosstalk exists between mTOR and STAT signaling cascades through the suppressor of cytokine signaling (SOCS) signaling [51]. Additionally, the SOCS family of proteins are negative feedback inhibitors of signaling induced by cytokines that act via the JAK/STAT pathway [52]. SOCS1 expression impedes STAT5 and STAT3 protein phosphorylation [53]. LPS pretreatment-induced SOCS3 inhibits IFN-β-induced STAT1 phosphorylation [54]. Therefore, the expression of the SOCS1 and SOCS3 was then evaluated. As shown in Fig. 7g, the mRNA and protein levels of SOCS1 and SOCS3 were significantly reduced, suggesting that mTOR may regulate both SOCS1/STAT3 and SOCS3/STAT1 signaling, which ultimately affected macrophage M1/M2 polarization.
TREM2 deficiency aggravated IRI-induced renal injury and fibrosis and promoted macrophage polarization in mice
Given that, in addition to UUO, the IRI procedure is also a well-recognized experimental model, which is widely used to study renal tubular injury and fibrosis [22, 23]. Therefore, we next conducted an IRI mice model to further confirm the effect of TREM2 on kidney injury and macrophage polarization. As expected, the H&E staining displayed that TREM2 deficiency remarkably aggravated renal injury induced by IRI on POD7 (Fig. 8a). Meanwhile, the fibrosis levels of mice kidney tissues were significantly increased after TREM2 knockout (Fig. 8b). Furthermore, consistent with the UUO results, the M1 macrophages (CD86+) and M2 macrophages (CD206+) both exhibited significant upregulation in the mice kidney according to flow cytometry data (Fig. 8c). From the above data, TREM2 deficiency aggravated IRI-induced renal injury and fibrosis and promoted macrophage polarization in mice.
Discussion
In the present study, we found that TREM2 expression was induced in the kidneys of UUO mice, consistent with observations in models of cerebral hemorrhage [55] and Alzheimer’s disease (AD) [56]. Accordingly, we hypothesized that TREM2 expression in UUO kidneys might be associated with the modulation of renal injury. To investigate the role of TREM2 in UUO-mediated kidney injury, we used Trem2−/− mice and validated the predominant expression of TREM2 in macrophages of UUO kidneys. Moreover, our IF findings indicated that, in addition to its expression on macrophage membranes, TREM2 was also evident in intercellular spaces, indicating the presence of secreted/shed soluble(s) TREM2 within the kidney. Thus, sTREM2 may play a crucial role in the modulation of the pathobiology of the UUO process as both membrane-associated and soluble protein forms, which may become the direction of our further research. Notably, in addition to macrophage, TREM2 is also expressed on part of dendritic cells. A previous study [57] has reported that TREM2-mediated dendritic cell-induced NO suppresses Th17 activation in UUO mice. Therefore, further investigation is necessary to explore the effect of TREM2 on the phenotype and function of dendritic cells. Furthermore, they found that tubular damage, myofibroblast accumulation, and fibrosis were not different between WT and Trem2−/− mice on day 7 of the UUO model, but significant differences became apparent on day 14. Possible reasons for the differences in the results of our study may be differences in the details of the modeling process, such as the degree of obstruction, the duration of surgery, and the surgical environment. To ensure the reliability of our results, we then utilized another well-recognized experimental model, the IRI model, which is more widely used to study renal tubular injury and fibrosis. As expected, we got a consistent conclusion. On POD7 following IRI, the fibrosis level was significantly promoted in Trem2−/− mice.
The TREM2 innate immune receptor has been extensively reported to promote macrophage survival under stress conditions [58]. Our data show that TREM2 deficiency reduced macrophage infiltration in mouse UUO kidneys. Correspondingly, our in vitro studies revealed that TREM2 deficiency inhibited macrophage survival and promoted apoptosis. Moreover, transcriptomic sequencing data of BMDM corroborated our findings. These observations align with previous studies that have demonstrated the ability of TREM2 to promote the survival of microglia, the primary innate immune cells of the CNS, that are similar to macrophages, and their proliferation in models of neurodegenerative diseases, such as AD and multiple sclerosis [59, 60].
Previous studies have documented that the absence of mTOR signaling in TREM2-deficient microglia is associated with compensatory upregulation of autophagy in patients with AD, both in vivo and in vitro [58]. Contrary to the inflammatory scenario we observed in UUO kidneys, microglial expression of inflammatory mediators is reported to be weaker in 5XFAD transgenic (AD model) mice lacking TREM2 [61]. However, we did not find any changes in autophagy (data not shown). Similarly, defective mTOR activation in TREM2-deficient macrophages resulted in macrophage dysfunction, reduced cell viability, and proliferation, as confirmed by an increase in caspase 3 activation and an increased incidence of apoptosis in Trem2−/− BMDM in vitro. Thus, while mTOR activation deficiency in TREM2-deficient macrophages may have reduced macrophage infiltration in UUO kidneys, inflammation in the kidney instead increased. This suggests that TREM2 may regulate mTOR signaling and influence events triggered by UUO via other pathways.
Multiple macrophage subtypes that release numerous cytokines play key roles in pathophysiological processes. Thus, M1 and M2 phenotypic polarization of macrophages may directly influence UUO pathologic events. While TREM2 has been reported to regulate macrophage polarization in several studies [62, 63], our findings reveal for the first time that TREM2 deficiency enhances macrophage activation and polarization toward both M1 and M2 cells in UUO kidneys. Among them, M1 macrophage markers, including iNOS, CD86, and MHC II, were significantly elevated, which explains part of the reason why TREM2 deficiency promotes renal injury and macrophage apoptosis. On the other hand, macrophage polarization towards M2 was consistent with the findings of Yang et al. showing that TREM2 activation in the CNS inhibits microglia/macrophage activation [55] and increases the number of CD206+ immunosuppressive macrophages [64]. However, it is a bit contradictory to our previous results because M2 is usually considered to have anti-inflammatory effects, contrary to M1. This may be due to the strong plasticity of macrophages, which differ significantly in different tissues, especially microglia in brain injury. This specificity of microglia may be due to their unique origin, resulting in a different transcriptome and epigenome from macrophages in other tissues [65]. This deserves more extensive research and study. Furthermore, Lisi et al. identified that proinflammatory activation of glioma cells induced a shift in microglia from a predominantly M2b phenotype to a mixture of M1 and M2a/b polarized cells [66]. Likewise, in our study, TREM2 deficiency promoted the expression of CD86, CD206, MHC II, iNOS, and Arg1 in macrophages, which suggested that macrophages were induced to shift toward a mixture of M1 and M2a/b by TREM2 deficiency. In sum, a spectrum or mixed phenotype of macrophage polarization may be present in TREM2 deficiency. Beyond the role of TREM2 in the mixed phenotype of macrophage polarization, how TREM2 regulates the efferocytosis of macrophage deserves further research. Lastly, TREM2 is expressed in the myeloid cells besides macrophages, which means conditional KO including Lyz2-Cre or CXCR3-Cre and TREM2 floxed mice would be more suitable to investigate their mechanisms in-depth.
Numerous studies have reported that macrophage phenotype and activation are regulated by JAK-STAT signaling [67, 68]. To investigate whether TREM2 might regulate macrophage polarization through JAK-STAT signaling, we assessed differences in expression levels of JAK2, STAT1, and STAT3, key proteins of the JAK-STAT pathway. Our data confirmed that TREM2 deficiency promoted macrophage polarization toward the M1 phenotype by upregulating STAT1 activation, and promoted macrophage polarization toward the M2 phenotype by upregulating STAT3 activation.
Our study revealed that TREM2 is a promising therapeutic target for CKD. Therefore, specific small molecules that activate TREM2 could be potentially developed to treat CKD in the future.
Conclusion
The present findings suggest that additional mechanisms whereby the protective effects of macrophage-expressed and secreted TREM2 on UUO kidneys are mediated merit investigation. In conclusion, our findings indicate that TREM2 deficiency inhibits macrophage survival and promotes apoptosis through the downregulation of Akt/mTOR signaling and that macrophage polarization via the JAK2-STAT1/3 pathways may exacerbate tubular injury, renal apoptosis, inflammation, and fibrosis in mice.
Supplementary information
Acknowledgements
We thank Yixin Xie and Liang Tan at Second Xiangya Hospital of Central South University for their technical assistance. We thank the Flow Cytometry Core at Second Xiangya Hospital of Central South University as well as the Division of Laboratory Animal Resources at Xiangya School of Medicine of Central South University.
Author contributions
YC, CC, HD, and LP conceived and designed the experiments. YC, CC, ZT, YW, KY, XQ, and PC performed the experiments. YC and CC analyzed the data. JL and XZ analyzed the pathological data. HD, ZQ, XJ, SS, YX, TL, YG, CF, and HZ contributed by procurement of reagents, materials, and analysis tools. YC, CC, AWT, and HD wrote the manuscript. AWT, XX, LP, ZQ, and HD approved the final version of the manuscript. YC and CC share co-first authorship, as each contributed key data to the manuscript. HD, ZQ, and AWT share co-corresponding authorship.
Funding
This work was supported by the National Natural Science Foundation of China (82070776, 82270796, 82200849, and 82370761), the Science and Technology Innovation Program of Hunan Province (2022RC3071), the Higher Education Teaching Reform Project of Central South University (2023jy110) and the Natural Science Foundation of Hunan Province (2023JJ40872).
Data availability
Complete and uncropped Western blotting imprints are uploaded as Supplementary Material. The raw sequencing data from this study have been deposited in the Genome Sequence Archive in BIG Data Center (http://bigd.big/ac.cn/), Beijing Institute of Genomics (BIG), Chinese Academy of Sciences, under the accession number: GRA0117711.
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All mice were maintained and housed in accordance with guidelines approved by the Animal Care Ethics Committee of Second Xiangya Hospital, People’s Republic of China, and ethical approval was obtained (protocol 2020229).
Footnotes
Edited by Boris Zhivotovsky
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Yan Cui, Chao Chen.
Contributor Information
Zhongquan Qi, Email: yxyyz@gxu.edu.cn.
Angus W. Thomson, Email: thomsonaw@upmc.edu
Helong Dai, Email: helong68888@csu.edu.cn.
Supplementary information
The online version contains supplementary material available at 10.1038/s41419-024-06756-w.
References
- 1.Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16:269–88. doi: 10.1038/s41581-019-0248-y. [DOI] [PubMed] [Google Scholar]
- 2.Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–32. doi: 10.1016/j.cell.2010.01.040. [DOI] [PubMed] [Google Scholar]
- 3.Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871–82. doi: 10.1016/j.cell.2010.02.029. [DOI] [PubMed] [Google Scholar]
- 4.Grande MT, Pérez-Barriocanal F, López-Novoa JM. Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy. J Inflamm. 2010;7:19. doi: 10.1186/1476-9255-7-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment. World J Transplant. 2015;5:52–67. doi: 10.5500/wjt.v5.i2.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Li J, Yang Y, Wang Y, Li Q, He F. Metabolic signatures of immune cells in chronic kidney disease. Expert Rev Mol Med. 2022;24:e40. doi: 10.1017/erm.2022.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Li HD, You YK, Shao BY, Wu WF, Wang YF, Guo JB, et al. Roles and crosstalks of macrophages in diabetic nephropathy. Front Immunol. 2022;13:1015142. doi: 10.3389/fimmu.2022.1015142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144–58. doi: 10.1038/s41581-019-0110-2. [DOI] [PubMed] [Google Scholar]
- 9.Sigalov AB. Inhibition of TREM-2 markedly suppresses joint inflammation and damage in experimental arthritis. Int J Mol Sci. 2022;23:8857. doi: 10.3390/ijms23168857. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Weng Y, Wang H, Li L, Feng Y, Xu S, Wang Z. Trem2 mediated Syk-dependent ROS amplification is essential for osteoclastogenesis in periodontitis microenvironment. Redox Biol. 2021;40:101849. doi: 10.1016/j.redox.2020.101849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hou J, Chen Y, Grajales-Reyes G, Colonna M. TREM2 dependent and independent functions of microglia in Alzheimer’s disease. Mol Neurodegener. 2022;17:84. doi: 10.1186/s13024-022-00588-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell. 2022;185:4153–69.e19. doi: 10.1016/j.cell.2022.09.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Alkan FK, Korkaya H. Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors. Signal Transduct Target Ther. 2020;5:264. doi: 10.1038/s41392-020-00383-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Khantakova D, Brioschi S, Molgora M. Exploring the impact of TREM2 in tumor-associated macrophages. Vaccines. 2022;10:943. doi: 10.3390/vaccines10060943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207–17. doi: 10.1016/j.cell.2020.05.003. [DOI] [PubMed] [Google Scholar]
- 16.Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38. doi: 10.1126/scisignal.2000500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.van Lengerich B, Zhan L, Xia D, Chan D, Joy D, Park JI, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models. Nat Neurosci. 2023;26:416–29. doi: 10.1038/s41593-022-01240-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Xue T, Ji J, Sun Y, Huang X, Cai Z, Yang J, et al. Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury. Acta Pharm Sin B. 2022;12:1885–98. doi: 10.1016/j.apsb.2021.10.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Perugorria MJ, Esparza-Baquer A, Oakley F, Labiano I, Korosec A, Jais A, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut. 2019;68:533–46. doi: 10.1136/gutjnl-2017-314107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Su VY, Yang KY, Chiou SH, Chen NJ, Mo MH, Lin CS, et al. Induced pluripotent stem cells regulate triggering receptor expressed on myeloid cell-1 expression and the p38 mitogen-activated protein kinase pathway in endotoxin-induced acute lung injury. Stem Cells. 2019;37:631–9. doi: 10.1002/stem.2980. [DOI] [PubMed] [Google Scholar]
- 21.Nakao T, Ono Y, Dai H, Nakano R, Perez-Gutierrez A, Camirand G, et al. DNAX activating protein of 12 kDa/triggering receptor expressed on myeloid cells 2 expression by mouse and human liver dendritic cells: functional implications and regulation of liver ischemia-reperfusion injury. Hepatology. 2019;70:696–710. doi: 10.1002/hep.30334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhu Y, Zhang M, Wang W, Qu S, Liu M, Rong W, et al. Polynucleotide phosphorylase protects against renal tubular injury via blocking mt-dsRNA-PKR-eIF2α axis. Nat Commun. 2023;14:1223. doi: 10.1038/s41467-023-36664-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Gu M, Jiang H, Tan M, Yu L, Xu N, Li Y, et al. Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating β-catenin palmitoylation. Nat Commun. 2023;14:6682. doi: 10.1038/s41467-023-42476-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Dai H, Watson AR, Fantus D, Peng L, Thomson AW, Rogers NM. Rictor deficiency in dendritic cells exacerbates acute kidney injury. Kidney Int. 2018;94:951–63. doi: 10.1016/j.kint.2018.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–30. doi: 10.1016/j.immuni.2015.02.005. [DOI] [PubMed] [Google Scholar]
- 26.Li T, Zhang Z, Bartolacci JG, Dwyer GK, Liu Q, Mathews LR, et al. Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection. J Clin Investig. 2020;130:5397–412. doi: 10.1172/JCI133008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hou J, Zhang J, Cui P, Zhou Y, Liu C, Wu X, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Investig. 2021;131:e135197. doi: 10.1172/JCI135197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Jung SH, Hwang BH, Shin S, Park EH, Park SH, Kim CW, et al. Spatiotemporal dynamics of macrophage heterogeneity and a potential function of Trem2(hi) macrophages in infarcted hearts. Nat Commun. 2022;13:4580. doi: 10.1038/s41467-022-32284-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Narváez A, Guiteras R, Sola A, Manonelles A, Morote J, Torras J, et al. siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice. PLoS ONE. 2019;14:e0215232. doi: 10.1371/journal.pone.0215232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zhang QF. Ulinastatin inhibits renal tubular epithelial apoptosis and interstitial fibrosis in rats with unilateral ureteral obstruction. Mol Med Rep. 2017;16:8916–22. doi: 10.3892/mmr.2017.7692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Tanase DM, Gosav EM, Radu S, Costea CF, Ciocoiu M, Carauleanu A, et al. The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity. Int J Mol Sci. 2019;20:5238. doi: 10.3390/ijms20205238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Chen Y, Mu L, Xing L, Li S, Fu S. Rhein alleviates renal interstitial fibrosis by inhibiting tubular cell apoptosis in rats. Biol Res. 2019;52:50. doi: 10.1186/s40659-019-0257-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Wang H, Qian J, Zhao X, Xing C, Sun B. β-Aminoisobutyric acid ameliorates the renal fibrosis in mouse obstructed kidneys via inhibition of renal fibroblast activation and fibrosis. J Pharm Sci. 2017;133:203–13. doi: 10.1016/j.jphs.2016.12.005. [DOI] [PubMed] [Google Scholar]
- 34.Xianyuan L, Wei Z, Yaqian D, Dan Z, Xueli T, Zhanglu D, et al. Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF-κB signaling pathways in a rat model of unilateral ureteral obstruction. Phytomedicine. 2019;53:274–85. doi: 10.1016/j.phymed.2018.09.009. [DOI] [PubMed] [Google Scholar]
- 35.Martínez-Klimova E, Aparicio-Trejo OE, Tapia E, Pedraza-Chaverri J. Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments. Biomolecules. 2019;9:141. doi: 10.3390/biom9040141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wang D, Xiong M, Chen C, Du L, Liu Z, Shi Y, et al. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy. Kidney Int. 2018;94:91–101. doi: 10.1016/j.kint.2017.12.025. [DOI] [PubMed] [Google Scholar]
- 37.Chen M, Menon MC, Wang W, Fu J, Yi Z, Sun Z, et al. HCK induces macrophage activation to promote renal inflammation and fibrosis via suppression of autophagy. Nat Commun. 2023;14:4297. doi: 10.1038/s41467-023-40086-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Wei L, Zhou Q, Tian H, Su Y, Fu GH, Sun T. Integrin β3 promotes cardiomyocyte proliferation and attenuates hypoxia-induced apoptosis via regulating the PTEN/Akt/mTOR and ERK1/2 pathways. Int J Biol Sci. 2020;16:644–54. doi: 10.7150/ijbs.39414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Kalitin NN, Ektova LV, Kostritsa NS, Sivirinova AS, Kostarev AV, Smirnova GB, et al. A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways. Chem Biol Interact. 2022;364:110056. doi: 10.1016/j.cbi.2022.110056. [DOI] [PubMed] [Google Scholar]
- 40.Kurosawa Y, Degrauw TJ, Lindquist DM, Blanco VM, Pyne-Geithman GJ, Daikoku T, et al. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. J Clin Investig. 2012;122:2837–46. doi: 10.1172/JCI59373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Xie Y, Hu X, Li S, Qiu Y, Cao R, Xu C, et al. Pharmacological targeting macrophage phenotype via gut-kidney axis ameliorates renal fibrosis in mice. Pharm Res. 2022;178:106161. doi: 10.1016/j.phrs.2022.106161. [DOI] [PubMed] [Google Scholar]
- 42.Wu Q, Sun S, Wei L, Liu M, Liu H, Liu T, et al. Twist1 regulates macrophage plasticity to promote renal fibrosis through galectin-3. Cell Mol Life Sci. 2022;79:137. doi: 10.1007/s00018-022-04137-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Luo Q, Deng D, Li Y, Shi H, Zhao J, Qian Q, et al. TREM2 insufficiency protects against pulmonary fibrosis by inhibiting M2 macrophage polarization. Int Immunopharmacol. 2023;118:110070. doi: 10.1016/j.intimp.2023.110070. [DOI] [PubMed] [Google Scholar]
- 44.Ross EA, Devitt A, Johnson JR. Macrophages: The good, the bad, and the gluttony. Front Immunol. 2021;12:708186. doi: 10.3389/fimmu.2021.708186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Li X, Pan J, Li H, Li G, Liu X, Liu B, et al. DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. 2020;11:4467. doi: 10.1038/s41467-020-18304-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, et al. Ruxolitinib alleviates renal interstitial fibrosis in UUO mice. Int J Biol Sci. 2020;16:194–203. doi: 10.7150/ijbs.39024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med. 2020;217:e20190103. doi: 10.1084/jem.20190103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Li X, Chen S, Zhang L, Niu G, Zhang X, Yang L, et al. Coinfection of porcine circovirus 2 and pseudorabies virus enhances immunosuppression and inflammation through NF-κB, JAK/STAT, MAPK, and NLRP3 pathways. Int J Mol Sci. 2022;23:4469. doi: 10.3390/ijms23084469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Cai Z, Zhang S, Wu P, Ren Q, Wei P, Hong M, et al. A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis. Clin Transl Med. 2021;11:e309. doi: 10.1002/ctm2.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Liu Y, Wang L, Li S, Zhang T, Chen C, Hu J, et al. Mechanical stimulation improves rotator cuff tendon-bone healing via activating IL-4/JAK/STAT signaling pathway mediated macrophage M2 polarization. J Orthop Translat. 2022;37:78–88. doi: 10.1016/j.jot.2022.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Saleiro D, Platanias LC. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015;36:21–9. doi: 10.1016/j.it.2014.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Liau NPD, Laktyushin A, Lucet IS, Murphy JM, Yao S, Whitlock E, et al. The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun. 2018;9:1558. doi: 10.1038/s41467-018-04013-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Gao AH, Hu YR, Zhu WP. IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway. Clin Transl Oncol. 2022;24:57–65. doi: 10.1007/s12094-021-02668-9. [DOI] [PubMed] [Google Scholar]
- 54.Ando T, Komatsu T, Naiki Y, Yokochi T, Watanabe D, Koide N. Pretreatment of LPS inhibits IFN-β-induced STAT1 phosphorylation through SOCS3 induced by LPS. Biomed Pharmacother. 2015;76:1–5. doi: 10.1016/j.biopha.2015.10.019. [DOI] [PubMed] [Google Scholar]
- 55.Chen S, Peng J, Sherchan P, Ma Y, Xiang S, Yan F, et al. TREM2 activation attenuates neuroinflammation and neuronal apoptosis via PI3K/Akt pathway after intracerebral hemorrhage in mice. J Neuroinflammation. 2020;17:168. doi: 10.1186/s12974-020-01853-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212:287–95. doi: 10.1084/jem.20142322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Lin CC, Chang TY, Lu YC, Wu YS, Huang W, Lo WC, et al. TREM-2 mediates dendritic cell-induced NO to suppress Th17 activation and ameliorate chronic kidney diseases. J Mol Med. 2022;100:917–31. doi: 10.1007/s00109-022-02201-7. [DOI] [PubMed] [Google Scholar]
- 58.Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170:649–63.e13. doi: 10.1016/j.cell.2017.07.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Cignarella F, Filipello F, Bollman B, Cantoni C, Locca A, Mikesell R, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 2020;140:513–34. doi: 10.1007/s00401-020-02193-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, et al. TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson’s disease models. FASEB J. 2019;33:12164–74. doi: 10.1096/fj.201900992R. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160:1061–71. doi: 10.1016/j.cell.2015.01.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, et al. Integrated analysis highlights the immunosuppressive role of TREM2(+) macrophages in hepatocellular carcinoma. Front Immunol. 2022;13:848367. doi: 10.3389/fimmu.2022.848367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Yu M, Chang Y, Zhai Y, Pang B, Wang P, Li G, et al. TREM2 is associated with tumor immunity and implies poor prognosis in glioma. Front Immunol. 2022;13:1089266. doi: 10.3389/fimmu.2022.1089266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Yang T, Zhang S, Yuan H, Wang Y, Cai L, Chen H, et al. Platinum-based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment. Angew Chem Int Ed Engl. 2023;62:e202213337. doi: 10.1002/anie.202213337. [DOI] [PubMed] [Google Scholar]
- 65.Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312–26. doi: 10.1016/j.cell.2014.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Lisi L, Stigliano E, Lauriola L, Navarra P, Dello Russo C. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro. 2014;6:171–83. doi: 10.1042/AN20130045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Hu L, Liu R, Zhang L. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors. Int Immunopharmacol. 2022;111:109095. doi: 10.1016/j.intimp.2022.109095. [DOI] [PubMed] [Google Scholar]
- 68.Hu WM, Liu SQ, Zhu KF, Li W, Yang ZJ, Yang Q, et al. The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis. Int Immunopharmacol. 2023;121:110505. doi: 10.1016/j.intimp.2023.110505. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Complete and uncropped Western blotting imprints are uploaded as Supplementary Material. The raw sequencing data from this study have been deposited in the Genome Sequence Archive in BIG Data Center (http://bigd.big/ac.cn/), Beijing Institute of Genomics (BIG), Chinese Academy of Sciences, under the accession number: GRA0117711.